Safety and efficacy of 36 months treatment of postmenopausal osteoporotic women with PTH (1–84)
Robert R. Recker(Creighton University), John Fox(Arrien Pharmaceuticals (United States)), Stephen Morris, C. Mautalén, Z. Man(Merck & Co., Inc., Rahway, NJ, USA (United States)), H. Greisen, Edward S. Leib(University of Vermont), José Zanchetta(Universidad del Salvador)
Cited by 2
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
A Mutation in the LDL Receptor–Related Protein 5 Gene Results in the Autosomal Dominant High–Bone-Mass Trait
|The American Journal of Human Genetics|2002|1.3k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
|Journal of Bone and Mineral Research|2004|1.2k